Bapineuzumab, a monoclonal antibody targeting β-amyloid (Aβ), showed no clinical benefit in patients with mild to moderate Alzheimer disease dementia in 2 recent phase 3 randomized placebo-controlled trials (Solloway S et al. N Engl J Med. 2014;370:322-333). The drug did, however, target and reduce Aβ accumulation in trial participants relative to placebo, according to a substudy that evaluated Alzheimer disease biomarkers. The finding supports “the hypotheses that bapineuzumab may not have been initiated early enough in the disease course, the doses were insufficient, or the most critical Aβ species were inadequately targeted,” the investigators stated (Liu E et al. Neurology. doi:10.1212/WNL.0000000000001877 [published online July 24, 2015]).
Slomski A. Anti–β-Amyloid Treatment May Need to Be Started Early. JAMA. 2015;314(12):1217. doi:10.1001/jama.2015.11782